These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22123613)

  • 1. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells.
    Qin K; Tian G; Li P; Chen Q; Zhang R; Ke YQ; Xiao ZC; Jiang XD
    J Neuroimmunol; 2012 Jan; 242(1-2):9-15. PubMed ID: 22123613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
    Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
    Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.
    Hua W; Yao Y; Chu Y; Zhong P; Sheng X; Xiao B; Wu J; Yang B; Mao Y; Zhou L
    J Neurooncol; 2011 Nov; 105(2):149-57. PubMed ID: 21479962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity.
    Sloan AE; Parajuli P
    J Neurooncol; 2003; 64(1-2):177-83. PubMed ID: 12952298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
    J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
    Kobayashi T; Yamanaka R; Homma J; Tsuchiya N; Yajima N; Yoshida S; Tanaka R
    Cancer Immunol Immunother; 2003 Oct; 52(10):632-7. PubMed ID: 12827308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
    Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
    Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
    Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination.
    Ardon H; Verbinnen B; Maes W; Beez T; Van Gool S; De Vleeschouwer S
    J Immunol Methods; 2010 Jan; 352(1-2):169-73. PubMed ID: 19874827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.
    Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
    Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells.
    Wang J; Liu P; Xin S; Wang Z; Li J
    Exp Cell Res; 2017 Nov; 360(2):66-73. PubMed ID: 28782555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
    Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity.
    Zhang B; Sun J; Yu SP; Chen C; Liu B; Liu ZF; Ren BC; Ming HL; Yang XJ
    Chin Med J (Engl); 2012 Dec; 125(24):4344-8. PubMed ID: 23253699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.